(AMGN) Amgen - Ratings and Ratios
Rheumatoid Arthritis, Psoriasis, Osteoporosis, Anemia, Oncology
AMGN EPS (Earnings per Share)
AMGN Revenue
Description: AMGN Amgen
Amgen Inc. (NASDAQ: AMGN) is a global biopharmaceutical company that discovers, develops, manufactures, and markets human therapeutics across a broad range of disease areas, including immunology, oncology, bone health, cardiovascular, and rare diseases.
The core portfolio features blockbuster biologics such as Enbrel (rheumatoid arthritis, psoriasis), Otezla (psoriasis, Behçet’s disease), Prolia/EvENITY (osteoporosis), XGEVA (skeletal-related events), Repatha (lipid-lowering), Nplate (immune thrombocytopenia), KYPROLIS (multiple myeloma), BLINCYTO (acute lymphoblastic leukemia), TEPEZZA (thyroid eye disease), and KRYSTEXXA (gout). Additional marketed products include Neulasta, Aimovig, LUMAKRAS, and others, extending Amgen’s reach into supportive care, migraine, and KRAS-mutated cancers.
Amgen distributes its medicines through wholesale pharmaceutical distributors, hospital and dialysis networks, and direct-to-consumer channels. The firm maintains strategic collaborations with AstraZeneca (TEZSPIRE), Novartis (Aimovig), UCB (EVENITY), Kyowa Kirin (rocatinlimab), and BeiGene (oncology), leveraging partner pipelines and shared commercialization resources.
Key recent financial metrics (FY 2023) show revenue of approximately $27 billion, a 5 % year-over-year growth driven largely by biosimilar-resistant biologics, R&D spending of $5.5 billion (≈20 % of sales), and diluted earnings per share of $6.30. The company declared a dividend of $1.30 per share, yielding roughly 3.2 % and reflecting its commitment to returning cash to shareholders.
Sector-level drivers that materially affect Amgen’s outlook include an aging U.S. population increasing demand for chronic-disease biologics, accelerating adoption of biosimilars that compress pricing on older products, and a robust pipeline of gene-editing and mRNA-based therapies that could reshape competitive dynamics in oncology and rare diseases.
For a deeper, data-rich assessment of Amgen’s valuation relative to these trends, you may find it useful to explore the analyst tools and model templates available on ValueRay.
AMGN Stock Overview
| Market Cap in USD | 159,048m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1983-06-17 |
AMGN Stock Ratings
| Growth Rating | 33.5% |
| Fundamental | 80.8% |
| Dividend Rating | 68.3% |
| Return 12m vs S&P 500 | -16.8% |
| Analyst Rating | 3.63 of 5 |
AMGN Dividends
| Dividend Yield 12m | 3.14% |
| Yield on Cost 5y | 4.76% |
| Annual Growth 5y | 8.90% |
| Payout Consistency | 100.0% |
| Payout Ratio | 43.1% |
AMGN Growth Ratios
| Growth Correlation 3m | -23.3% |
| Growth Correlation 12m | 7.6% |
| Growth Correlation 5y | 86.6% |
| CAGR 5y | 9.37% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.38 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.92 |
| Sharpe Ratio 12m | 0.79 |
| Alpha | -14.87 |
| Beta | 0.480 |
| Volatility | 21.56% |
| Current Volume | 1930.6k |
| Average Volume 20d | 2342k |
| Stop Loss | 289.8 (-3%) |
| Signal | 0.82 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (6.62b TTM) > 0 and > 6% of Revenue (6% = 2.09b TTM) |
| FCFTA 0.12 (>2.0%) and ΔFCFTA 5.76pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 17.93% (prev 18.39%; Δ -0.46pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.14 (>3.0%) and CFO 12.01b > Net Income 6.62b (YES >=105%, WARN >=100%) |
| Net Debt (48.18b) to EBITDA (15.90b) ratio: 3.03 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.31 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (541.0m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 64.47% (prev 63.30%; Δ 1.18pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 39.04% (prev 34.03%; Δ 5.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.51 (EBITDA TTM 15.90b / Interest Expense TTM 2.95b) >= 6 (WARN >= 3) |
Altman Z'' 0.39
| (A) 0.07 = (Total Current Assets 26.73b - Total Current Liabilities 20.48b) / Total Assets 87.90b |
| (B) -0.29 = Retained Earnings (Balance) -25.71b / Total Assets 87.90b |
| (C) 0.12 = EBIT TTM 10.38b / Avg Total Assets 89.40b |
| (D) 0.09 = Book Value of Equity 7.43b / Total Liabilities 80.47b |
| Total Rating: 0.39 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 80.78
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 5.12% = 2.56 |
| 3. FCF Margin 30.38% = 7.50 |
| 4. Debt/Equity 7.57 = -2.50 |
| 5. Debt/Ebitda 3.03 = -1.81 |
| 6. ROIC - WACC (= 8.47)% = 10.59 |
| 7. RoE 97.92% = 2.50 |
| 8. Rev. Trend 89.03% = 6.68 |
| 9. EPS Trend 65.25% = 3.26 |
What is the price of AMGN shares?
Over the past week, the price has changed by +2.99%, over one month by +8.77%, over three months by +1.00% and over the past year by -3.90%.
Is Amgen a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AMGN is around 300.96 USD . This means that AMGN is currently overvalued and has a potential downside of 0.72%.
Is AMGN a buy, sell or hold?
- Strong Buy: 10
- Buy: 5
- Hold: 14
- Sell: 1
- Strong Sell: 2
What are the forecasts/targets for the AMGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 311.7 | 4.3% |
| Analysts Target Price | 311.7 | 4.3% |
| ValueRay Target Price | 328.2 | 9.8% |
Last update: 2025-10-11 05:00
AMGN Fundamental Data Overview
P/E Trailing = 24.1562
P/E Forward = 13.7363
P/S = 4.555
P/B = 21.5548
P/EG = 0.9577
Beta = 0.48
Revenue TTM = 34.91b USD
EBIT TTM = 10.38b USD
EBITDA TTM = 15.90b USD
Long Term Debt = 53.76b USD (from longTermDebt, last quarter)
Short Term Debt = 2.44b USD (from shortTermDebt, last quarter)
Debt = 56.20b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 48.18b USD (from netDebt column, last quarter)
Enterprise Value = 207.22b USD (159.05b + Debt 56.20b - CCE 8.03b)
Interest Coverage Ratio = 3.51 (Ebit TTM 10.38b / Interest Expense TTM 2.95b)
FCF Yield = 5.12% (FCF TTM 10.61b / Enterprise Value 207.22b)
FCF Margin = 30.38% (FCF TTM 10.61b / Revenue TTM 34.91b)
Net Margin = 18.96% (Net Income TTM 6.62b / Revenue TTM 34.91b)
Gross Margin = 64.47% ((Revenue TTM 34.91b - Cost of Revenue TTM 12.40b) / Revenue TTM)
Gross Margin QoQ = 67.15% (prev 63.58%)
Tobins Q-Ratio = 2.36 (Enterprise Value 207.22b / Total Assets 87.90b)
Interest Expense / Debt = 1.26% (Interest Expense 708.0m / Debt 56.20b)
Taxrate = 8.67% (136.0m / 1.57b)
NOPAT = 9.48b (EBIT 10.38b * (1 - 8.67%))
Current Ratio = 1.31 (Total Current Assets 26.73b / Total Current Liabilities 20.48b)
Debt / Equity = 7.57 (Debt 56.20b / totalStockholderEquity, last quarter 7.43b)
Debt / EBITDA = 3.03 (Net Debt 48.18b / EBITDA 15.90b)
Debt / FCF = 4.54 (Net Debt 48.18b / FCF TTM 10.61b)
Total Stockholder Equity = 6.76b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.53% (Net Income 6.62b / Total Assets 87.90b)
RoE = 97.92% (Net Income TTM 6.62b / Total Stockholder Equity 6.76b)
RoCE = 17.15% (EBIT 10.38b / Capital Employed (Equity 6.76b + L.T.Debt 53.76b))
RoIC = 14.52% (NOPAT 9.48b / Invested Capital 65.28b)
WACC = 6.05% (E(159.05b)/V(215.25b) * Re(7.78%) + D(56.20b)/V(215.25b) * Rd(1.26%) * (1-Tc(0.09)))
Discount Rate = 7.78% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 0.09%
[DCF Debug] Terminal Value 79.04% ; FCFE base≈8.65b ; Y1≈9.12b ; Y5≈10.76b
Fair Price DCF = 350.1 (DCF Value 188.48b / Shares Outstanding 538.4m; 5y FCF grow 5.91% → 3.0% )
EPS Correlation: 65.25 | EPS CAGR: 9.42% | SUE: 3.13 | # QB: 4
Revenue Correlation: 89.03 | Revenue CAGR: 12.37% | SUE: 1.97 | # QB: 1
Additional Sources for AMGN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle